MX2023004435A - Compuestos y composiciones para el tratamiento de la criptosporidiosis. - Google Patents
Compuestos y composiciones para el tratamiento de la criptosporidiosis.Info
- Publication number
- MX2023004435A MX2023004435A MX2023004435A MX2023004435A MX2023004435A MX 2023004435 A MX2023004435 A MX 2023004435A MX 2023004435 A MX2023004435 A MX 2023004435A MX 2023004435 A MX2023004435 A MX 2023004435A MX 2023004435 A MX2023004435 A MX 2023004435A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- cryptosporidiosis
- compositions
- treatment
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 208000008953 Cryptosporidiosis Diseases 0.000 title abstract 2
- 206010011502 Cryptosporidiosis infection Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención se refiere a compuestos de Formula I: (ver Fórmula) I o una sal farmacéuticamente aceptable, un tautómero o estereoisómero de dichos compuestos, en donde las variables son como se definen en el presente documento. La presente invención proporciona además composiciones farmacéuticas que comprenden dichos compuestos, y métodos de uso de dichos compuestos para el método de tratamiento, prevención, inhibición, mejora o erradicación de la patología y/o sintomatología de la criptosporidiosis mediante la administración de dicho compuesto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063091866P | 2020-10-14 | 2020-10-14 | |
| PCT/IB2021/059376 WO2022079616A1 (en) | 2020-10-14 | 2021-10-12 | Compounds and compositions for the treatment of cryptosporidiosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004435A true MX2023004435A (es) | 2023-05-08 |
Family
ID=78302850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004435A MX2023004435A (es) | 2020-10-14 | 2021-10-12 | Compuestos y composiciones para el tratamiento de la criptosporidiosis. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4229055A1 (es) |
| JP (1) | JP2023545452A (es) |
| CN (1) | CN116368137A (es) |
| AR (1) | AR123766A1 (es) |
| AU (1) | AU2021362803A1 (es) |
| CA (1) | CA3197199A1 (es) |
| MX (1) | MX2023004435A (es) |
| TW (1) | TW202229277A (es) |
| UY (1) | UY39466A (es) |
| WO (1) | WO2022079616A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201728325A (zh) * | 2016-01-21 | 2017-08-16 | 諾華公司 | 治療隱孢子蟲病之化合物及組合物 |
-
2021
- 2021-10-12 CN CN202180069247.7A patent/CN116368137A/zh active Pending
- 2021-10-12 CA CA3197199A patent/CA3197199A1/en active Pending
- 2021-10-12 EP EP21794994.0A patent/EP4229055A1/en active Pending
- 2021-10-12 TW TW110137677A patent/TW202229277A/zh unknown
- 2021-10-12 WO PCT/IB2021/059376 patent/WO2022079616A1/en active Application Filing
- 2021-10-12 AU AU2021362803A patent/AU2021362803A1/en active Pending
- 2021-10-12 AR ARP210102815A patent/AR123766A1/es unknown
- 2021-10-12 UY UY0001039466A patent/UY39466A/es unknown
- 2021-10-12 MX MX2023004435A patent/MX2023004435A/es unknown
- 2021-10-12 JP JP2023522570A patent/JP2023545452A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022079616A1 (en) | 2022-04-21 |
| CN116368137A (zh) | 2023-06-30 |
| CA3197199A1 (en) | 2022-04-21 |
| US20220112189A1 (en) | 2022-04-14 |
| JP2023545452A (ja) | 2023-10-30 |
| AU2021362803A1 (en) | 2023-06-01 |
| AR123766A1 (es) | 2023-01-11 |
| UY39466A (es) | 2022-05-31 |
| TW202229277A (zh) | 2022-08-01 |
| EP4229055A1 (en) | 2023-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210563A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| MX2022001784A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos. | |
| TW200639159A (en) | Treatment of pain | |
| PH12018501489A1 (en) | Compounds and compositions for the treatment of cryptosporidiosis | |
| MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
| MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| MX2023003627A (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer. | |
| MX2020007985A (es) | Inhibicion del canal ionico receptor de potencial transitorio a1. | |
| MX2022009967A (es) | Compuestos para el tratamiento de la infeccion por coronavirus. | |
| CR20220538A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| MX2021011144A (es) | Derivados de las benzodiazepinas como inhibidores del vsr. | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
| CR20210602A (es) | Compuestos de pirrolidina | |
| MX2022012472A (es) | Agente para el tratamiento de lesion renal aguda inducida por medio de contraste. | |
| MX2023004435A (es) | Compuestos y composiciones para el tratamiento de la criptosporidiosis. | |
| WO2020251871A3 (en) | Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors | |
| MX2020009287A (es) | Nuevo compuesto y composicion farmaceutica que lo comprende. | |
| MX2023010065A (es) | Derivados de diazepina utiles en el tratamiento de clostridium difficile. | |
| MX2019003585A (es) | Derivados de tetrahidropiridina y su uso como agentes antibacterianos. | |
| MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. | |
| PH12020551620A1 (en) | Compositions for preventing or treating dry eye |